Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Basal Cell Cancer
New basal cell cancer study findings have been reported by L. Eibenschurz and colleagues
February 3rd, 2009
According to recent research from Rome, Italy, "Basal cell carcinoma (BCC) is the most common cancer affecting Caucasians and, due to its large size or to the pool condition of the patient, it call be difficult to treat it with conventional therapies: in these cases photodynamic therapy with methyl aminolevulinate (MAL-PDT) may represent a good option. A retrospective non-comparative follow-up Study was performed to test the response of giant and large BCC to MAL-PDT." "Twelve patients with 14 giant BCC (>= 5 cm) and 5 patients with 5 large BCC (4-5 cm) were treated with MAL-PDT; they were evaluated 6 months after the end of the treatment to define the initial Cure...
Source: Cancer Weekly (2009-02-03)
|
